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ABSTRACT
The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a 
genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. 
However, association with atherothrombotic cardiovascular events is less clear, with limited evidence 
from large trials. Here, we tested association of rs12041331 with cardiovascular events and aspirin use in 
a randomized trial population of healthy older individuals. We undertook post-hoc analysis of N=13,547 
participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. 
Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrolment, and were 
randomized to either 100 mg daily low-dose aspirin or placebo for median 4.7 years follow-up. We used 
Cox proportional hazard regression to model the relationship between rs12041331 and the ASPREE 
primary cardiovascular disease endpoint (CVD), and composites of major adverse cardiovascular events 
(MACE) and ischaemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and 
intracranial bleeding (ICB). We performed whole-population analysis using additive and dominant 
inheritance models, then stratified by treatment group. Interaction effects between genotypes and 
treatment group were examined. We observed no statistically significant association (P<0.05) in the 
population, or by treatment group, between rs12041331 and cardiovascular or bleeding events in either 
model. We also found no significant interaction effects between rs12041331-A and treatment group, for 
CVD (P=0.65), MACE (P=0.32), STROKE (P=0.56), MHEM (P=0.59) or ICB (P=0.56). The genetic 
variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in 
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1 INTRODUCTION
2 Interindividual variability in response to antiplatelet medications including aspirin can result in 
3 inadequate platelet inhibition and subsequent cardiovascular and cerebrovascular events. Clinical and 
4 anthropometric factors are known to contribute to variable aspirin efficacy including age, gender, body 
5 mass index (BMI), diabetes mellitus (DM), compliance, and certain drug-drug interactions(1-3). In 
6 addition, heritability estimates, as assessed by ex vivo agonist-stimulated platelet aggregation, suggest that 
7 a large proportion of variation in response to aspirin may be attributable to genetic factors(4). Indeed, 
8 multiple pharmacogenetic investigations ranging from candidate gene reports to genome-wide association 
9 studies have been conducted to identify novel genetic determinants of aspirin response. Identification of 
10 genetic polymorphisms that lead to suboptimal platelet control may have important implications in 
11 primary and secondary prevention of adverse clinical events in patients with an indication for this 
12 medication.
13 The platelet endothelial aggregation receptor 1 (PEAR1) gene encodes a type 1 membrane protein, that is 
14 highly expressed in platelets and endothelial cells(5) and critical in haematological processes including 
15 megakaryopoiesis, thrombopoiesis, and αIIbβ3-mediated platelet aggregation(6, 7). Genetic variants in 
16 the PEAR1 gene have been associated with platelet aggregation(8, 9) and in response to antiplatelet agents 
17 including aspirin(10-12), clopidogrel(13), ticagrelor(14), and prasugrel(15). Most notably, an intronic 
18 variant rs12041331 in the PEAR1 gene is among the strongest genetic modifiers of platelet aggregation, 
19 particularly in those treated with aspirin, and results in allele-specific differences in H3K4Me1 
20 methylation leading to differential gene and protein expression(11, 16, 17). Despite the evidence 
21 demonstrating the influence of PEAR1 rs12041331 on agonist-stimulated platelet aggregation in aspirin-
22 treated patients, the impact of this variant on thrombotic and bleeding events remains unclear.
23 In this investigation, we assessed the interaction between PEAR1 rs12041331 and randomized aspirin use 
24 in 13,547 participants of the Aspirin in Reducing Events in the Elderly (ASPREE) trial. Specifically, 
25 individuals with no previous diagnosis of atherothrombotic cardiovascular disease were randomized to 
26 either 100 mg daily low-dose aspirin or placebo for median 4.7 years and relationships between 
27 rs12041331 genotypes and cardiovascular events, as well as clinically significant bleeding events, were 
28 examined. Moreover, gene x environment (i.e. aspirin treatment) interaction models were used to test 
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30 METHODS
31 Study population
32 Details of the ASPREE trial are described previously(18, 19). Briefly, ASPREE was a double-blind, 
33 randomized (1:1), placebo-controlled trial to examine the effect of daily low-dose aspirin on disability-
34 free survival in healthy older individuals(19-21). At enrolment, the 19,114 participants of the ASPREE 
35 trial had no current symptoms or prior history of cardiovascular events, including: myocardial infarction, 
36 heart failure, stroke, transient ischemic attack, atrial fibrillation or high blood pressure. Participants also 
37 had no dementia diagnosis, physical disability, or illness likely to cause death within 5 years at enrolment. 
38 Participants were followed prospectively, monitored for a range of primary and secondary outcomes, 
39 including cardiovascular events, dementia, persistent disability and cancer. Participants were enrolled 
40 from March 2010 through December 2014, with follow-up data collected until June 2017 (median follow-
41 up of 4.7 years).  All investigational protocols were approved by local Institutional Review Boards across 
42 Australia and the United States and conformed to the principles outlined in the Declaration of Helsinki. 
43 Each participant gave informed consent prior to enrolment. 
44 Outcomes
45 We analysed the relationship between aspirin use and the common variant PEAR1 rs12041331, in relation 
46 to clinically adjudicated cardiovascular and bleeding events in ASPREE. Endpoints analysed included the 
47 primary cardiovascular disease endpoint in the ASPREE study (CVD), and composites of major  
48 cardiovascular events considered most likely to be impacted by aspirin; including major adverse 
49 cardiovascular events (MACE) and ischaemic stroke (STROKE); and clinically significant bleeding 
50 events, including major hemorrhage (MHEM) and intracranial bleeding (ICB). Details of ASPREE 
51 endpoints are described previously(21). 
52 Genetic analysis
53 Ethical approval for genetic analysis was obtained from the Alfred Hospital Human Research Ethics 
54 Committee (390/15). Genome-wide SNP genotyping of N=14,177 samples collected by the ASPREE 
55 Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research 
56 Array (Thermo Fisher Scientific, CA, USA) following standard protocols, at the Ramaciotti Centre for 
57 Genomics, University of New South Wales, Australia. Samples were excluded based on poor quality 
58 control (QC) metrics or genotyping performance (N=426) and other filters including gender discordance 
59 (N=80), and relatedness (N=124). In the final dataset, a total of N=13,547 samples from individuals of 
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61 were excluded based on genotyping rate (<95%) and Hardy-Weinberg equilibrium. Imputation was 
62 performed on European-ancestry samples using the haplotype reference consortium (HRC) panel on the 
63 University of Michigan imputation server(22). Post-imputation QC removed all variants with <0.3 
64 imputation quality scores. The imputation quality score of the variant rs12041331 was R2=0.99. 
65 Statistical analysis
66 We use Cox proportional hazards regression models to analyze the relationship between rs12041331-A 
67 allele and cardiovascular events, adjusting for variables related to cardiovascular risk, including: age, 
68 gender, smoking status, alcohol intake, high density lipoproteins (HDL), low density lipoprotein (LDL)-
69 cholesterol, triglycerides (TG), total cholesterol (TC), hypertension, body mass index (BMI), diabetes 
70 mellitus (DM) and statin use prior to enrolment. Analysis of the entire cohort (N=13,547) was performed 
71 using an additive model of inheritance (GG vs AG vs AA) and dominant model (GG vs AG/AA), 
72 followed by stratified analysis of the placebo (N=6,806) and aspirin (N=6,741) groups, separately. Then 
73 the modifying effect of the rs12041331-A genotype on association between incident CVD events and 
74 aspirin treatment was analysed using an interaction term in a multivariable Cox regression model using 
75 participants from both groups, under both the additive and dominant genetic models. We calculated the 
76 minimal detectable effect for all endpoints under both models. All analyses were performed with Stata 
77 15.1 (Stata Corp., Tex., USA) and R (R Core Team, 2014). P-values < 0.05 were considered as 
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79 RESULTS
80 The 13,547 genotyped participants had a median age of 73.9 years and were 54.7% female. The 
81 distributions of age, sex, plasma lipids and BMI variables were balanced between the groups (Table 1). 
82 Genotype distribution for rs12041331 was also balanced between the placebo and aspirin groups, with 
83 GA heterozygotes found at 16.3% (N=1,112) and 15.3 % (N=1,034) respectively, and AA homozygotes 
84 at 0.9% (N=64) and 0.9% (N=60) respectively (Figure 1, Table 2). 
85 We did not observe evidence of association between PEAR1 rs12041331 and cardiovascular or bleeding 
86 events when stratifying the cohort by treatment effect (Table 3), based on using an additive (Figure 2) or 
87 dominant (Figure 3) models of inheritance.  In the placebo group, when comparing major allele 
88 homozygotes to heterozygotes or minor allele homozygotes using the additive model, no difference in 
89 event rate was noted for CVD (P=0.27 and P=0.62, respectively), MACE (P=0.66 and P=0.73, 
90 respectively), STROKE (P=0.92 and P=0.95, respectively), MHEM (P=0.57 and P=0.61, respectively) or 
91 ICB (P=0.92 and P=0.95, respectively). Hazard ratio [HR] point estimates (Table 3) were generally in the 
92 same direction as observed when evaluating the entire cohort (see below) (Table S1). 
93 Similarly, there was no evidence to suggest that PEAR1 rs12041331 genotype impacted cardiovascular or 
94 bleeding event rate in participants treated with aspirin (Table 3).  In individuals randomized to aspirin,  
95 rs12041331 A-allele carrier status did not result in statistically significant differences in atherothrombotic 
96 event rates (CVD, MACE and STROKE) or bleeding events (MHEM and ICB) regardless if individuals 
97 carried 1 (CVD P=0.14, MACE P=0.11, STROKE P=0.51, MHEM P=0.92, and ICB P=0.51) or 2 (CVD 
98 P=0.78, MACE P=0.85, STROKE P=0.76, MHEM P=N/A, and ICB P=0.76) copies of the A-allele 
99 (Table 3). We repeated these analyses using a dominant model of inheritance (wild-type GG vs all 
100 AA/AG carriers) and also found no significant associations (Table S2).
101 In the combined cohort (both aspirin- and placebo-treated groups), no association was observed between 
102 rs12041331 A-allele carrier status and atherothrombotic events for either the additive (Table S1) or 
103 dominant (Table S2) genetic models.  Specifically, no statistical difference in event rates for CVD, 
104 MACE and STROKE were seen when comparing PEAR1 rs12041331 major allele homozygotes to either 
105 heterozygotes (HR=0.81; 95% confidence interval [CI] 0.64 to 1.02; P=0.07, HR=0.84, 95% CI 0.64 to 
106 1.09, P=0.19, and HR=0.94, 95% CI 0.64 to 1.38, P=0.74, respectively) or minor allele homozygotes 
107 (HR=1.10; 95% CI 0.50 to 2.44; P=0.50, HR=1.22, 95% CI 0.51 to 2.90, P=0.65, and HR=1.13, 95% CI 
108 0.28 to 4.53, P=0.86, respectively).  Similarly, no correlation between genotype and MHEM or ICB was 
109 observed when comparing rs12041331 major allele homozygotes to either heterozygotes (HR=0.96; 95% 
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111 homozygotes (HR=0.27; 95% CI 0.04 to 1.93; P=0.19 and HR=1.13, 95% CI 0.28 to 4.53, P=0.28, 
112 respectively). 
113 Using a multivariable Cox regression model, adjusting for age, gender, smoking status, alcohol intake, 
114 HDL, LDL-cholesterol, TG, TC, hypertension, BMI, diabetes mellitus and statin use prior to enrolment, 
115 we found no evidence of an interaction effect between rs12041331 genotypes and aspirin treatment under 
116 the additive or dominant inheritance model, for incident CVD, MACE, ischemic stroke, major 
117 haemorrhage and intracranial bleeding (Table 4, Tables S3-8). For calculations of minimal detectable 
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119 DISCUSSION
120 There is considerable evidence that the PEAR1 receptor is a critical part of platelet aggregation in 
121 response to several agonists, and that rs12041331 is a strong genetic determinant of platelet 
122 aggregation(5, 6, 12, 23, 24).  However, there is less data regarding the impact of this variant on 
123 cardiovascular event risk, in untreated individuals or in patients prescribed antiplatelet medication.  In the 
124 current study, we sought to evaluate the impact of PEAR1 SNP rs12041331, a well-described genetic 
125 variant implicated in aspirin-related platelet function, on MACE and clinically significant bleeding events 
126 in a large healthy cohort of elderly individuals randomized to either aspirin or placebo in the ASPREE 
127 trial.  In analyses of the entire cohort or when stratifying by treatment effect (i.e. aspirin vs. placebo), 
128 using either an additive or dominant model of inheritance, we observed no evidence of association for 
129 rs12041331 with increased risk of experiencing a thrombotic or bleeding event.  Furthermore, we 
130 observed no significant interaction effects between PEAR1 genotype, aspirin use and clinical outcomes 
131 using either an additive or dominant model. 
132 Since its identification in 2005, multiple investigations have been published highlighting the role of 
133 PEAR1 in several important biological processes(5).  The most extensively studied of these processes has 
134 been platelet aggregation; however, other proposed functions of this receptor include maintenance of 
135 endothelial cell function(13, 25), megakaryopoiesis and thrombopoiesis(7), neoangiogenesis(26), 
136 leukocyte function(17), and neuronal phagocytosis(27, 28).  These and other publications have prompted 
137 numerous genetic studies attempting to correlate PEAR1 polymorphisms with related phenotypes and 
138 diseases.  From these investigations, rs12041331 has been among the most thoroughly studied, with the 
139 strongest effect on platelet-related phenotypes, and established functional effect on PEAR1 expression. 
140 Previously, rs12041331 A-allele carriers have been shown to have significantly lower DNA methylation 
141 in a CpG-island which contains binding sites for the methylation-sensitive transcription factor CTCF 
142 compared to GG homozygotes, presumably leading to differences in gene and protein expression 
143 observed by others at this locus(11, 16).
144 Given the effect of rs12041331 on PEAR1 expression and platelet-related processes, recent investigations 
145 have focused on the impact of this polymorphism on cardiovascular-related diseases with mixed results.  
146 Initial reports in percutaneous coronary intervention patients treated with aspirin and clopidogrel showed 
147 that A-allele carriers of this variant experienced MACE (HR=2.62; 95% CI 0.96 - 7.10; P=0.06) and 
148 cardiovascular-related death (HR=3.97; 95% CI 1.10-14.31; P=0.04) more frequently compared to GG 
149 homozygotes (29).  However, these results were not confirmed in a Flemish population, which reported 
150 no association with several different cardiovascular and cerebrovascular phenotypes when using 
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152 findings were consistent with a subsequent publication showing no association between PEAR1 
153 rs12041331 and ischemic events in Chinese patients with an acute coronary syndrome treated with aspirin 
154 and clopidogrel (HR=1.30, 95% CI 0.74 - 2.29, P=0.07), although it should be noted that statistical power 
155 was likely quite low in this study given a limited sample size of 196 patients(31).  
156 Most recently, Xu et al. prospectively assessed rs12041331 in over 2,400 Chinese patients with acute 
157 coronary syndrome or stable coronary artery disease undergoing stent implantation and treated with 
158 aspirin and clopidogrel(32).  Based on PEAR1 genotype, they observed significantly different ADP-
159 induced platelet aggregation (29.1, 25.4, and 22.9 for genotypes GG, GA, and AA, respectively, 
160 P=0.0005) and detected differences in the 30-day incidence of a composite cardiovascular phenotype 
161 consisting of cardiovascular death, nonfatal myocardial infarction, and ischemic stroke (HR=2.78, 95% 
162 CI 1.13 - 6.82, P=0.03).  Positive associations with deep vein thrombosis in those with sticky platelet 
163 syndrome as well as coronary artery aneurysm in individuals with Kawasaki disease have also been 
164 shown by PEAR1 rs12041331 genotype(33, 34).  
165 Further studies have suggested a genotype x aspirin interaction exists whereby aspirin-treated carriers of 
166 rs12041331 minor (A) allele have enhanced risk of experiencing a clinical event compared to carriers of 
167 the same allele who are not treated with aspirin(29).  Specifically, it was observed in stable coronary 
168 artery disease patients of European descent that rs12041331 A-allele carriers treated with aspirin have 
169 significantly increased risk of myocardial infarction (odds ratio [OR] = 2.08, 95% CI 1.01 - 4.09; 
170 P=0.048) compared to those who were not exposed to aspirin (OR = 0.25, 95% CI 0.03-2.03, P=0.19).  
171 Similar trends were observed using a composite cardiovascular outcome consisting of death, non-fatal 
172 stroke, and non-fatal myocardial infarction (OR = 1.62, 95% CI 0.91-2.90, P=0.10 and OR = 0.54, 95% 
173 CI 0.22 - 1.31, P=0.16, respectively)(29).  Evidence also suggests that the PEAR1 receptor may be able to 
174 exert cardiovascular-related effects through processes that are independent of platelet function (e.g. 
175 endothelial-related effects).  Investigation of other molecular processes that are regulated by PEAR1 
176 would likely allow for more targeted investigation of effects that may modify cardiovascular risk.
177 It is noteworthy that all previous studies discussed above have been undertaken in populations known to 
178 be affected by cardiovascular disease. The present study, however, has been undertaken in a highly 
179 selected population of healthy older individuals with no previous diagnosis of atherothrombotic 
180 cardiovascular disease, and in the context of primary prevention. Our study results, therefore, must be 
181 interpreted accordingly. 
182 In our investigation, which is the largest study of PEAR1 rs12041331 and cardiovascular outcomes 
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184 events or clinically significant bleeding in the entire cohort, regardless of aspirin use (Table 3). We also 
185 found no significant effects in interaction analyses using either the additive (Table 4, Tables S3-7) or 
186 dominant (Table S8) genetic model. Given that the minor allele of this variant resulted in lower agonist-
187 stimulated platelet aggregation in prior investigations, we also assessed whether aspirin-dependent effects 
188 could modify the relationship between PEAR1 genotype and clinically significant bleeding events.  
189 Consistent with our analyses pertaining to thrombotic outcomes, no association was observed between 
190 rs12041331 and bleeding in both placebo- or aspirin-randomized individuals and no statistically 
191 significant interaction was observed between aspirin treatment and genotype on occurrence of bleeding 
192 events.
193 While our data suggests that this polymorphism is not an important contributor to clinical events in a 
194 healthy older population, in the setting of primary prevention, additional studies are warranted, 
195 investigating the effect of rs12041331 on MACE in other populations, and including the general 
196 population, and patients with higher cardiovascular burden, such as those following a coronary 
197 intervention procedure, and/or on a dual antiplatelet therapy regimen. 
198 Strengths of our study include the sample size, being the largest evaluation of PEAR1 rs12041331 
199 conducted to date, with regards to cardiovascular outcomes and aspirin use. To our knowledge, it is also 
200 the only study to examine the effect of rs12041331 on clinically significant bleeding events.  In addition, 
201 the prospective, randomized nature of the study design implemented in the ASPREE trial allowed us to 
202 confidently assess the interaction between PEAR1 genotype and aspirin use on adverse events in cohorts 
203 that were well-matched for clinical and anthropometric characteristics known to influence cardiovascular 
204 and bleeding risk(18). Central adjudication of cardiovascular and bleeding events allowed for blinded 
205 evaluation of suspected outcomes and ultimately allowed us to maximize data consistency while 
206 minimizing potential biases.  
207 Limitations of our study include the highly selected nature of the ASPREE population, and the 
208 predominance of European ancestry, which limit the generalizability of our results to other populations. 
209 Participants enrolled into the ASPREE trial were elderly, generally healthy individuals with no known 
210 atherothrombotic cardiovascular disease and were randomized to aspirin in the context of primary 
211 prevention.  Therefore, our study results may not be indicative of data obtained in patients with more 
212 severe cardiovascular burden and/or in the context of secondary prevention.  Furthermore, ethnicity-
213 specific analyses were not performed in the current investigation.  While prior investigations in European-
214 , African- and Asian-derived populations have shown consistent effects of PEAR1 rs12041331 genotype 
215 with regards to platelet aggregation, the vast majority of ASPREE participants were Caucasian (~93%). 
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217 origins especially given that the minor allele frequency of rs12041331 varies significantly among such 
218 groups.  Our study had very few events in the AA homozygote group, which limited the interpretation of 
219 results from the additive genetic model used in the primary analysis. To account for this, we conducted 
220 analysis using a dominant model, and found similar results. Finally, it is important to note that 
221 participants were randomized to low dose aspirin in this study (i.e. 100 mg/daily).  If a true interaction 
222 between PEAR1 genotype and aspirin use exists, it is possible that such an interaction may be dependent 
223 on aspirin dose.
224 It is also noteworthy that low-dose aspirin did not significantly decrease CVD, MACE, or stroke events 
225 versus placebo in the overall ASPREE trial (21). The lack of an aspirin treatment effect in the ASPREE 
226 healthy elderly population must be considered when interpreting of the lack of associations found in 
227 genetic analysis of PEAR1 rs12041331 in this cohort. It is possible that the selection bias that occurred as 
228 a result of the strict ASPREE enrolment criteria, excluding any individuals with a history of diagnosed 
229 cardiovascular events, has resulted in ascertainment of a unique population where genetic effects are 
230 diminished or attenuated. This is indeed consistent with others studies that have shown a diminished 
231 effect of genetic risk factors as a function of age in other contexts (35, 36). 
232 Based on our calculations of minimal detectable differences between rs12041331 genotypes and the 
233 endpoints analysed in the ASPREE trial (Tables S9-10), it is possible that larger study populations or 
234 meta-analyses may uncover significant effects of PEAR1 and aspirin use on cardiovascular or bleeding 
235 events. However, it is also possible that in such larger study populations, investigations may find the 
236 effect of rs12041331 moving closer towards zero. Further post-hoc analysis of other large aspirin trials is 
237 therefore warranted, as new datasets from other large trials become available.
238 In conclusion, we could not replicate previous findings suggesting that PEAR1 rs12041331 was an 
239 important genetic determinant of cardiovascular outcomes.  Furthermore, no effects of this variant on 
240 clinically significant bleeding was observed in the ASPREE study.  While differences in study designs 
241 and participant populations may, in part, explain these divergent results, our data do provide robust 
242 evidence that genetic variation in PEAR1 do not contribute to cardiovascular disease risk in relatively 
243 healthy older individuals regardless of aspirin treatment.  Additional well-powered investigations in 
244 patients with high-risk clinical indications would likely be helpful to determine the role, if any, PEAR1 
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246 STUDY HIGHLIGHTS:
247 o What is the current knowledge on the topic? 
248 Identification of genetic factors that influence aspirin response may facilitate more personalized 
249 antiplatelet treatment, and targeted prevention of cardiovascular disease. Yet identification of 
250 pharmacogenomic variants of high clinical effect for aspirin has been challenging. Previous studies 
251 suggest that genetic variation in the platelet endothelial aggregation receptor 1 (PEAR1) gene results in 
252 altered aspirin efficacy. However, association of PEAR1 genotypes with cardiovascular events is less 
253 clear.
254
255 o What question did this study address? 
256 Our study, the largest study of PEAR1 and cardiovascular outcomes to date, examined the effect of 
257 rs12041331 genotypes and aspirin use on cardiovascular and bleeding events in a population of 13,547 
258 healthy older individuals without a history of atherothrombotic cardiovascular disease enrolled in the 
259 ASPirin in Reducing Events in the Elderly (ASPREE) trial.
260
261 o What does this study add to our knowledge?
262 We observed no association between genotypes and these outcomes, and no interaction with aspirin use in 
263 the ASPREE population. Our study indicates PEAR1 genetic variation does not influence aspirin primary 
264 prevention in healthy older individuals without a history of cardiovascular events.
265
266 o How might this change clinical pharmacology or translational science?
267 Our study represents an important finding that contributes to the evolving pharmacogenomics evidence-
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FIGURE LEGENDS
Figure 1. Schematic Overview (Graphical Abstract). We examined the relationship between 
rs12041331 genotypes and cardiovascular and bleeding events in a randomised placebo-controlled study 
population of N=13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. 
Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrolment, and were 
randomized to either 100 mg daily low-dose aspirin or placebo for a median 4.7 years of follow-up. 
Endpoints analysed included the primary cardiovascular disease endpoint in the ASPREE study (CVD), 
and composites of major adverse cardiovascular events (MACE) and ischaemic stroke; and bleeding 
events including major hemorrhage and intracranial bleeding. Details of ASPREE endpoints are described 
previously (21). The modifying effect of the rs12041331-A genotype on association with cardiovascular 
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361 Figure 2: Cumulative incidence curves (additive genetic model). We undertook cumulative incidence 
362 analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by rs12041331 
363 genotypes using an additive model of genetic inheritance; GG wild type (blue curves), AG heterozygotes 
364 (red curves), and AA homozygotes (yellow curves). Events analysed included the primary cardiovascular 
365 disease endpoint in the ASPREE study (CVD) (a-b), and composites of major adverse cardiovascular 
366 events (MACE) (c-d) and ischaemic stroke (STROKE) (e-f); and the ASPREE clinically significant 












370 Figure 3: Cumulative incidence curves (dominant genetic model). We undertook cumulative 
371 incidence analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by 
372 rs12041331 genotypes using a dominant model of genetic inheritance; GG wild type (blue curves) versus 
373 AG/AA carriers (red curves). Events analysed included the primary cardiovascular disease endpoint in the 
374 ASPREE study (CVD) (a-b), and composites of major adverse cardiovascular events (MACE) (c-d) and 
375 ischaemic stroke (STROKE) (e-f); and the ASPREE clinically significant bleeding endpoint sub-
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Table 1: Characteristics of Genotyped Participants by Treatment Status. Data summaries are median 








Age at randomization (yrs) 73.9 (71.7, 77.3) 73.9 (71.7, 77.3) 73.9 (71.7, 77.3)
65-73.9 yr 3,485 (51.2%) 3,446 (51.1%) 6,931 (51.2%)
≥74 yr 3,321 (48.8%) 3,295 (48.9%) 6,616 (48.8%)
Gender
Female 3,716 (54.6%) 3,691 (54.8%) 7,407 (54.7%)
Male 3,090 (45.4%) 3,050 (45.2%) 6,140 (45.3%)
Blood lipid levels 
(mg/DL at baseline)
LDL-C 119.9 (96.7, 140.0) 116.0 (96.0, 139.2) 116.0 (96.7 to 139.2)
HDL-C 58.0 (50.3, 69.6) 58.0 (50.0, 69.6) 58.0 (50.3 to 69.6)
TG 106.3 (79.7, 141.7) 106.3 (79.7, 141.7) 106.3 (79.7 to 141.7)
TC 201.1 (177.9, 228.2) 201.1 (177.9, 228.2) 201.1 (177.9 to 228.2)
BMI kg/m2 (baseline) 27.4 (24.9-30.5) 27.4 (24.9-30.5) 27.4 (24.9 to 30.5)
Underweight, <20 112 (1.7%) 119 (1.8%) 231 (1.7%)
Normal, 20-24.9 1,635 (24.1%) 1,643 (24.5%) 3,278 (24.3%)
Overweight, 25-29.9 3,112 (45.9%) 3,037 (45.2%) 6,149 (45.6%)
Obese, ≥30 1,917 (28.3%) 1,914 (28.5%) 3,831 (28.4%)
Statin use* 2,369 (34.8%) 2,384 (35.4%) 4,753 (35.1%)
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378 Table 2. Genotype Distribution by Treatment Status. Genome-wide SNP genotyping of N=14,177 
379 samples collected by the ASPREE Healthy Ageing Biobank was performed using the Axiom 2.0 
380 Precision Medicine Diversity Research Array (Thermo Fisher Scientific, CA, USA) following standard 
381 protocols. A total of N=13547 samples passed post-genotyping quality control (QC) filters. Samples were 
382 excluded based on filters related to gender discordance, genotyping rate (<95%), relatedness, Hardy-
383 Weinberg equilibrium, and ethnicity. Imputation was performed on European-ancestry samples using the 
384 haplotype reference consortium (HRC) panel on the Michigan imputation server (22). Post-imputation 
385 QC removed all variants with <0.3 imputation quality scores. The imputation quality score of the variant 
386 rs12041331 was R2=0.99. 
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Table 3: Association of rs12041331 Genotypes with ASPREE Cardiovascular Disease and Bleeding 
Events in Aspirin and Placebo Treatment Groups. We used Cox proportional hazard regression to 
model the relationship between rs12041331 genotypes with cardiovascular and bleeding events. 
Endpoints analysed included the ASPREE cardiovascular disease endpoint (CVD), and sub-components 
of major adverse cardiovascular events (MACE) and ischaemic stroke (STROKE); and the ASPREE 
clinically significant bleeding endpoint (CSB), and sub-components of major hemorrhage (MHEM) and 
intracranial bleeding (ICB). Details of ASPREE endpoints are described previously (21). HR adj: Hazard 
ratio, adjusted for age, gender, smoking status, alcohol intake, high density lipoproteins, low density 
lipoprotein cholesterol, triglycerides, total cholesterol, hypertension, body mass index, diabetes mellitus 
and statin use prior to enrolment (multivariable Cox regression analysis).
ASPREE Cardiovascular Disease Endpoint (CVD)
PLACEBO ASPIRIN
NO CVD    
n (%)
 CVD





    n (%)
 CVD
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AA 61 (95.3) 4 (6.3)
1.22
(0.40, 3.71)
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AA 63 (98.4) 1 (1.6)
0.94
(0.13, 6.63)
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Table 4. Tests of Interaction Effect between treatment group and the rs12041331-A Genotype 
on ASPREE Cardiovascular Disease and Bleeding Events. The modifying effect of the 
rs12041331-A genotype on association between incident CVD events and aspirin treatment was 
analysed using an interaction term in a multivariable Cox regression model using participants from 
both groups, adjusted for age, gender, smoking status, alcohol intake, high density lipoproteins, low 
density lipoprotein cholesterol, triglycerides, total cholesterol, hypertension, body mass index, 
diabetes mellitus and statin use prior to enrolment. Endpoints analysed included the ASPREE 
cardiovascular disease endpoint (CVD), and sub-components of major adverse cardiovascular events 
(MACE) and ischaemic stroke (STROKE); and the ASPREE clinically significant bleeding endpoint 
(CSB), and sub-components of major hemorrhage (MHEM) and intracranial bleeding (ICB). Details 
of ASPREE endpoints are described previously (21).
rs12041331 CVD MACE STROKE MHEM ICB
z P z P z P z P z P
GA # 
Aspirin
-0.46 0.649 -0.99 0.321 -0.58 0.561 0.54 0.591 -0.58 0.561
AA # 
Aspirin
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